Novel triplet regimen yields promising response in advanced-phase chronic myeloid leukemia
80% of advanced-phase CML or Philadelphia chromosome-positive AML patients achieved bone marrow remission with decitabine, venetoclax, and ponatinib combination therapy, according to a Phase II trial published in The Lancet Haematology.
Reference News
80% of advanced-phase CML and Philadelphia chromosome-positive AML patients achieved bone marrow remission with decitabine, venetoclax, and ponatinib combination therapy, according to a Phase II trial published in The Lancet Haematology.
80% of advanced-phase CML or Philadelphia chromosome-positive AML patients achieved bone marrow remission with decitabine, venetoclax, and ponatinib combination therapy in a Phase II trial, published in The Lancet Haematology.
80% of advanced-phase CML patients achieved bone marrow remission with decitabine, venetoclax, and ponatinib in a Phase II trial, according to MD Anderson researchers. The trial included patients with accelerated or myeloid blast phases of CML and Philadelphia chromosome-positive AML.
80% of patients with advanced-phase CML or Philadelphia chromosome–positive AML achieved bone marrow remission with a novel triplet combination of decitabine, venetoclax, and ponatinib in a phase II clinical trial, according to a study by Short et al in The Lancet Haematology.
80% of advanced-phase CML or Philadelphia chromosome-positive AML patients achieved bone marrow remission with decitabine, venetoclax, and ponatinib combination therapy, according to a Phase II trial published in The Lancet Haematology.